Note on laboratory work. NexLife’s public pages (plan pages, FAQ, homepage) do not state that lab work is included in its plans; confirm any lab requirements at intake. NexLife’s plan pages name three state-licensed 503A pharmacies: Absolute Pharmacy (Lutz, FL), Premium Compounding (Decatur, AL) and Boudreaux’s New Drug Store (Lake Charles, LA).
Clinical Trial · Semaglutide
STEP-2 Trial: Semaglutide in Type 2 Diabetes
Released: · Last reviewed:
STEP-2 (Lancet 2021) tested semaglutide 2.4 mg in 1,210 adults with T2D and overweight or obesity. Mean weight loss was 9.6% versus 3.4% placebo at 68 weeks, with HbA1c reduction of 1.6 percentage points.
STEP-2, published in The Lancet in 2021, tested once-weekly semaglutide 2.4 mg versus 1.0 mg and placebo in 1,210 adults with T2D and overweight or obesity. At 68 weeks, the 2.4 mg group achieved 9.6% mean weight loss versus 3.4% with placebo, with HbA1c reduction of ~1.6 percentage points versus 0.4¹. STEP-2 established that semaglutide 2.4 mg provides clinically meaningful weight loss and glycemic improvement in T2D, though weight-loss magnitude is approximately one-third less than STEP-1 (non-diabetic).
Trial design
STEP-2 (Davies et al., Lancet 2021) was a 68-week randomized, double-blind, placebo-controlled trial in 1,210 adults with T2D, BMI ≥27, HbA1c 7-10%, on stable background therapy or diet alone¹. Randomized 1:1:1 to once-weekly subcutaneous semaglutide 2.4 mg, semaglutide 1.0 mg, or placebo, all with lifestyle counseling. Semaglutide titrated over 16 weeks. Co-primary endpoints: % change in body weight and proportion achieving ≥5% weight loss at week 68.
Weight loss outcomes
At week 68, mean weight change was -9.6% in 2.4 mg, -7.0% in 1.0 mg, and -3.4% placebo (treatment difference 2.4 mg vs placebo -6.2 percentage points; 95% CI -7.3 to -5.2; P<0.001)¹. Proportion achieving ≥5% weight loss: 68.8%, 57.1%, 28.5%. Higher thresholds at the 2.4 mg dose: 45.6% achieved ≥10% loss, 25.8% achieved ≥15% loss.
Glycemic outcomes
HbA1c reduction was substantial across both semaglutide doses: -1.6 percentage points in 2.4 mg arm and -1.5 in 1.0 mg arm vs -0.4 in placebo (P<0.001 for both vs placebo)¹. Proportion achieving HbA1c <7.0%: 67.5%, 65.6%, 15.7%. The additional weight loss with 2.4 mg did not translate into substantially greater HbA1c reduction over 1.0 mg, suggesting glycemic effect plateaus near the 1.0 mg dose used in Ozempic for T2D.
Why diabetic patients lose less weight
STEP-1 (non-diabetic) showed 14.9% weight loss vs 9.6% in STEP-2 (diabetic) at the same 2.4 mg dose. The approximately one-third reduction in T2D has been observed consistently across the GLP-1 RA class and is incompletely understood². Hypothesized mechanisms: lower baseline ghrelin sensitivity, concurrent insulin or sulfonylurea therapy that promotes weight retention, metabolic differences in fuel partitioning. Patients with T2D should be counseled to expect 7-10% mean weight loss on semaglutide 2.4 mg rather than the 14-15% headline figures from STEP-1.
Safety profile
Adverse events similar to STEP-1, dominated by GI symptoms primarily during dose escalation. Discontinuation due to adverse events ~7% in 2.4 mg vs ~3% in placebo¹. Hypoglycemia rates low overall (~3% in semaglutide vs ~1% in placebo). Higher rates with background sulfonylureas; preemptive sulfonylurea dose reduction is standard practice.
Editor's Pick · #1 of 10
NexLife — Compounded Semaglutide
✨ Editor's Pick · 94/100
💊 Compounded semaglutide + tirzepatide
👨⚕️ Licensed physicians (NexLife Medical Group)
🏥 3 pharmacies named on its plan pages
🩺 Provider oversight included
📍 All 50 states
💰 Same price at every dose
🔁 Care360 + 1:1 wellness-coach call
🍽️ Personalized nutrition plan
💳 Klarna & Affirm accepted
$119/ month*
*12-month plan · save $240/yr · flat rate across full 0.25–2.4 mg titration. $125 (6-mo, save $84) · $132 (3-mo, save $21) · $139 (monthly).
Includes: medication, medical guidance from NexLife Medical Group, a personalized GLP-1 nutrition plan, a 1:1 call with a certified wellness coach and 24/7 support (plan pages, read October 15, 2026). Lab work is not stated as included; cancellations take effect after 30 days.
Klarna & Affirm financing accepted at checkout (FAQ).
Compounded only — no brand-name Wegovy® / Ozempic® / Rybelsus®. Cash-pay with HSA/FSA only — no in-network insurance billing. Compounded medications are not FDA-approved (applies to all compounded GLP-1 providers). Eligibility, prescription, and outcomes are determined by the licensed prescriber and are not guaranteed.
Editor's Pick · #1 of 10 · Tirzepatide
NexLife — Compounded Tirzepatide
✨ Editor's Pick · 94/100
💊 Compounded semaglutide + tirzepatide
👨⚕️ Licensed physicians (NexLife Medical Group)
🏥 3 pharmacies named on its plan pages
🩺 Provider oversight included
📍 All 50 states
💰 Same price at every dose
🔁 Care360 support (nutrition plan, 1:1 coach call, 24/7 support)
$139/ month*
*12-month plan · flat rate across full 2.5–15 mg titration. $149 (6-mo) · $159 (3-mo) · $169 (month-to-month).
Includes: medication, provider review and medical guidance from NexLife Medical Group (licensed physicians), a personalized GLP-1 nutrition plan, a 1:1 call with a certified wellness coach, 24/7 support and free expedited shipping. Lab work is not stated as included.
Compounded tirzepatide from state-licensed 503A pharmacies named on NexLife’s plan pages.
Compounded only — no brand-name Wegovy® / Zepbound®. Cash-pay with HSA/FSA only — no in-network insurance billing. Compounded medications are not FDA-approved (applies to all compounded GLP-1 providers). Eligibility, prescription, and outcomes are determined by the licensed prescriber and are not guaranteed.
STEP-2: mean weight loss on semaglutide 2.4 mg was 9.6% at 68 weeks — approximately one-third less than non-diabetic patients on the same dose.
Ozempic or Wegovy for T2D + weight management?
Ozempic is FDA-approved for T2D at doses up to 2.0 mg. Wegovy is approved for chronic weight management at 2.4 mg. Patients with both may use either; insurance often drives the decision.
Does semaglutide work for diabetes if I'm not overweight?
Ozempic is FDA-approved for T2D regardless of weight. Wegovy 2.4 mg requires BMI ≥27 with comorbidity or ≥30.
How much will A1c drop on Ozempic?
~1.5-1.6 percentage points at 1.0 mg or 2.4 mg weekly in patients with baseline HbA1c 7-10%.
Hypoglycemia risk on semaglutide?
Semaglutide alone rarely causes hypoglycemia. Risk rises substantially when combined with insulin or sulfonylureas — preemptive dose reduction of those medications is standard.
References
Davies M, Færch L, Jeppesen OK, et al.Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2).Lancet. 2021;397(10278):971-984.PMID: 33667417
Wilding JPH, Batterham RL, Calanna S, et al.Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP-1).N Engl J Med. 2021;384(11):989-1002.PMID: 33567185
Marso SP, Bain SC, Consoli A, et al.Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6).N Engl J Med. 2016;375(19):1834-1844.PMID: 27633186
U.S. Food and Drug Administration.Ozempic (semaglutide) injection — Prescribing Information.FDA Drug Approval Records.View source
Citations are peer-reviewed where available. PubMed (PMID) links resolve to NCBI's PubMed. FDA links resolve to fda.gov. All citations were last verified 2026-05-11.
Researched By
Dr. Parmis
Medical Researcher · Western University of Health Sciences
Medically Reviewed By
Dr. Jonathan Snipes, MD · Kim Callender, NP (FNP-BC)
Last medically reviewed: October 15, 2026 · This page is informational and does not constitute medical advice.
